Advances in the allostery of angiotensin II type 1 receptor
Cell & Bioscience, 2023 Angiotensin II type 1 receptor (AT1R) is a promising therapeutic target for cardiovascular diseases. Compared with orthosteric ligands, allosteric modulators attract considerable attention for drug development due to their unique advantages of high ...
Xi Zhang +4 more
doaj +3 more sources
Angiotensin II Type 1 Receptor Autoantibodies in Primary Aldosteronism [PDF]
Hormone and Metabolic Research, 2020 Primary aldosteronism (PA) is the most common form of endocrine hypertension. Agonistic autoantibodies against the angiotensin II type 1 receptor (AT1R-Abs) have been described in transplantation medicine and women with pre-eclampsia and more recently in
Meyer, Lucie +3 more
core +12 more sources
Enhancement of Adipocyte Browning by Angiotensin II Type 1 Receptor Blockade. [PDF]
PLoS ONE, 2016 Browning of white adipose tissue (WAT) has been highlighted as a new possible therapeutic target for obesity, diabetes and lipid metabolic disorders, because WAT browning could increase energy expenditure and reduce adiposity.
Kana Tsukuda +12 more
doaj +4 more sources
Angiotensin II Type 1 Receptor Autoantibodies in Postural Tachycardia Syndrome [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 BackgroundBoth the adrenergic and renin‐angiotensin systems contribute to orthostatic circulatory homeostasis, which is impaired in postural orthostatic tachycardia syndrome (POTS).
Xichun Yu +9 more
doaj +3 more sources
The angiotensin II type 1 receptor and receptor-associated proteins [PDF]
Cell Research, 2001 The mechanisms of regulation, activation and signal transduction of the angiotensin II (Ang II) type 1 (AT1) receptor have been studied extensively in the decade after its cloning. The AT1 receptor is a major component of the renin-angiotensin system (RAS). It mediates the classical biological actions of Ang II.
Deng‐Fu Guo +3 more
openalex +3 more sources
Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist [PDF]
FEBS Letters, 2001 We investigated the expression of angiotensin II type 1 receptor (AT1) in pancreatic cancer. Both AT1 mRNA and protein were expressed in human pancreatic cancer tissues and cell lines. Binding assays showed that pancreatic cancer cells have specific binding sites for angiotensin II and that binding could be eliminated by treatment with a selective AT1 ...
Yoshifumi Fujimoto +3 more
openalex +5 more sources
Novel regulations of the angiotensin II receptor type 1 by calmodulin. [PDF]
Biochem Pharmacol, 2018 The angiotensin II receptor type 1 (AT1R) mediates many Ca2+-dependent actions of angiotensin II (AngII). Calmodulin (CaM) is a key transducer of Ca2+ signals in cells. Two locations on the receptor's submembrane domains (SMD) 3 and 4 are known to interact with CaM.
Ehlers K +4 more
europepmc +5 more sources
Type 1 angiotensin II receptors in human endometrium [PDF]
Molecular Human Reproduction, 1996 From evidence based on the use of specific receptor subtype antagonists, it has generally been assumed that human uterine tissue contains only type 2 (AT2) angiotensin II (AII) receptor subtype. Using a monoclonal antibody, 6313/G2, directed against a specific sequence in the extracellular domain of the type 1 AII receptor (AT1), in immunocytochemical ...
Alison J. Hall +6 more
openaire +3 more sources
Angiotensin II Type 2 Receptor Antagonizes Angiotensin II Type 1 Receptor–Mediated Cardiomyocyte Autophagy [PDF]
Hypertension, 2009 Autophagy has emerged as an important process in the pathogenesis of cardiovascular diseases, but the proximal triggers for autophagy are unknown. Angiotensin II plays a central role in the pathogenesis of cardiac hypertrophy and heart failure. In this study, we used angiotensin II type 1 (AT 1 ) and type 2 (AT
Porrello, Enzo R. +6 more
openaire +4 more sources
Assessing the Relationship of Angiotensin II Type 1 Receptors with Erythropoietin in a Human Model of Endogenous Angiotensin II Type 1 Receptor Antagonism [PDF]
Cardiorenal Medicine, 2015 <b><i>Hypothesis/Introduction:</i></b> Angiotensin II (Ang II) has been shown to control erythropoietin (EPO) synthesis as Ang II type 1 receptor (AT1R) blockers block Ang-II-induced EPO oversecretion. To further explore the involvement of AT1R in processes controlling EPO levels, plasma EPO and mononuclear cell NADPH oxidase 4 (
CALO', LORENZO +7 more
openaire +4 more sources